Click Therapeutics
We're Hiring!
Click Therapeutics Company Growth, Stability & Outlook
What People Are Saying About Click Therapeutics
-
Investor Backing & Capital Strength: Recent financings include a strategic Series C with Dassault Syst�fsmes/Medidata (March 2025) and a Series D in April 2026 led by Boehringer Ingelheim tied to CT-155 commercialization. The restructuring with Boehringer also involved additional funding as commercialization responsibilities shifted to Click.
-
Product Line Growth: FDA authorizations for Rejoyn (MDD, 2024) and CT-132 (migraine prevention, 2025), plus the acquisition of AspyreRx (type 2 diabetes), expand the marketed and near-market portfolio. The launch of "Click SE" and CT-155s Breakthrough designation and positive pivotal data further broaden the offering toward potential submission.
-
Strategic Partnerships: Collaborations with Boehringer Ingelheim, Otsuka, and Dassault Syst�fsmes/Medidata, along with a 2026 venture with Ultrahuman, indicate strong external validation and routes to commercialization. Partner activity includes Boehringer transferring commercialization duties for CT-155 to Click.
